 |
|
|
| |
Integrated Efficacy and Safety of Glecaprevir/Pibrentasvir in Patients With Psychiatric Disorders
|
| |
| |
Reported by Jules Levin
EASL 2018 April 11-15 Paris France
David Back1, Pamela Belperio2, Mark Bondin3, Francesco Negro4, Andrew H Talal5, Caroline Park3, Yang Lei3, Brett Pinksy3, Eric Crown3, Federico Mensa3, Fiona Marra1
1University of Liverpool, Liverpool, United Kingdom; 2US Department of Veterans Affairs, VA Palo Alto Healthcare System, Palo Alto, California, United States; 3AbbVie Inc., North Chicago, Illinois, United States;
4University of Geneva, Geneva, Switzerland; 5Jacobs School of Medicine and Biomedical Sciences, University of Buffalo, Buffalo, New York, United States
|
| |
|
|
|
|
|
